Moleculin Biotech announces U.S. patent issue notification for Annamycin

Moleculin Biotech announced it has received an Issue Notification from the United States Patent and Trademark Office, USPTO, for U.S. Patent number 11,980,634 titled, “Method of Reconstituting Liposomal Annamycin” to be issued on May 14, 2024 to Moleculin and The University of Texas System Board of Regents. Walter Klemp, CEO and Chairman of Moleculin, stated, “We remain committed to establishing a robust patent estate for Annamycin and driving its development forward. In addition to our recently announced composition of matter patent for Annamycin, we believe we are well positioned for the potential partnering discussions which we expect to have in the near future. The issuance of this patent further underscores the importance and proprietary nature of the innovation that makes this next generation anthracycline possible and bolsters our confidence in its potential to address a number of high-value indications where there remains unmet medical need.”